George Fennell sold $7.3M of IDXX
Executive Vice President at IDEXX LABORATORIES INC /DE. 11,345 shares at an average of $646.72, traded Feb 10, 2026, filed Feb 11, 2026.
Score components
- +15RoleOfficer
- +25Trade size$7.3M at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.5%, 3m -18.5%, 6m -12.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874716-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | MOption exercise Common Stock | +1,476 | $67.85 | $100k | 9,823 | Feb 11, 2026 |
| Feb 10, 2026 | MOption exercise Common Stock | +11,345 | $67.85 | $770k | 21,168 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -1,130 | $643.00 | $727k | 20,038 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -397 | $644.02 | $256k | 19,641 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -2,161 | $645.25 | $1.4M | 17,480 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -2,782 | $646.23 | $1.8M | 14,698 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -1,060 | $647.21 | $686k | 13,638 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -966 | $648.78 | $627k | 12,672 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -2,809 | $649.26 | $1.8M | 9,863 | Feb 11, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock | -40 | $650.32 | $26k | 9,823 | Feb 11, 2026 |
| Feb 9, 2026 | MOption exercise Incentive Stock Option (right-to-buy)derivative | -1,476 | $0.00 | $0 | 0 | Feb 11, 2026 |
| Feb 10, 2026 | MOption exercise Non-Qualified Stock Option (right-to-buy)derivative | -11,345 | $0.00 | $0 | 0 | Feb 11, 2026 |
Related signals
Other insiders at IDEXX LABORATORIES INC /DE and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | IDXXsell IDEXX LABORATORIES INC /DE | Lawrence D Kingsley director | $1.2M 2,203 shares | -19% | |
| 55Moderate | IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $1.1M 1,758 shares | -9% | |
| 55Moderate | IDEXX LABORATORIES INC /DE | Jonathan Jay Mazelsky President and CEO | $15M 23,326 shares | -22% | |
| 60Notable | IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $1.8M 2,693 shares | -12% | |
| 50Moderate | IDEXX LABORATORIES INC /DE | Michael G Erickson Executive Vice President | $3.4M 5,371 shares | -30% | |
| 59Moderate | IDEXX LABORATORIES INC /DE | Sophie V. Vandebroek director | $920k 1,464 shares | -69% | |
| 35Weak | IDXXsell IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $6.6M 9,425 shares | -31% | |
| 60Notable | IDEXX LABORATORIES INC /DE | M Anne Szostak director | $1.4M 2,187 shares | -89% | |
| 43Moderate | IDEXX LABORATORIES INC /DE | Michael G Erickson Executive Vice President | $264k 406 shares | -3% | |
| 37Weak | IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $788k 1,200 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.